|
NR2C2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.14860000014028E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.59690000000246E-05 |
| Normal-vs-Stage2 |
3.443100E-04 |
| Normal-vs-Stage3 |
2.21579999903909E-08 |
| Normal-vs-Stage4 |
1.29199999998608E-06 |
| Stage1-vs-Stage2 |
6.063400E-01 |
| Stage1-vs-Stage3 |
1.968420E-02 |
| Stage1-vs-Stage4 |
8.278300E-02 |
| Stage2-vs-Stage3 |
2.603400E-01 |
| Stage2-vs-Stage4 |
4.259800E-01 |
| Stage3-vs-Stage4 |
7.862400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.40879999946486E-07 |
| Normal-vs-AfricanAmerican |
4.926000E-02 |
| Normal-vs-Asian |
3.382200E-03 |
| Caucasian-vs-AfricanAmerican |
2.226400E-01 |
| Caucasian-vs-Asian |
3.090400E-01 |
| AfricanAmerican-vs-Asian |
7.099000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.45629999995334E-06 |
| Normal-vs-Female |
5.40119999947741E-07 |
| Male-vs-Female |
9.428200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.80790000000287E-05 |
| Normal-vs-Age(41-60Yrs) |
1.75700000004664E-06 |
| Normal-vs-Age(61-80Yrs) |
8.7877000010117E-08 |
| Normal-vs-Age(81-100Yrs) |
1.177380E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.878010E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.940300E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.282590E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.793400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.038010E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.271600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.182200E-04 |
| Classical-VS-Follicular |
4.604100E-03 |
| Classical-VS-Other |
6.114000E-01 |
| Classical-VS-Normal |
9.87080000000029E-05 |
| Tall-VS-Follicular |
3.102800E-01 |
| Tall-VS-Other |
2.869400E-01 |
| Tall-VS-Normal |
2.52309999559941E-08 |
| Follicular-VS-Other |
6.729800E-01 |
| Follicular-VS-Normal |
1.99250000054718E-07 |
| Other-VS-Normal |
5.165700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.64550000023323E-07 |
| Normal-vs-N1 |
1.060990E-03 |
| N0-vs-N1 |
3.664400E-01 |
|
|
